Welcome to our dedicated page for Singular Genomics Systems news (Ticker: OMIC), a resource for investors and traders seeking the latest updates and insights on Singular Genomics Systems stock.
This page provides a historical news archive for Singular Genomics Systems, Inc., which previously traded on Nasdaq under the symbol OMIC. The company describes itself as a life science technology company developing next-generation sequencing (NGS) and multiomics technologies, including the G4® Sequencing Platform and the G4X™ Spatial Sequencer. Its news releases document product milestones, spatial biology data presentations, corporate transactions and capital markets developments.
Readers can review announcements about the G4 Sequencing Platform, which Singular Genomics characterizes as a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. News items also cover progress on the G4X Spatial Sequencer, described as a system under development that will apply the company’s proprietary sequencing technology as an in situ readout for transcriptomics, proteomics and fluorescent H&E in tissue with spatial context.
The archive includes updates on spatial multiomics performance in FFPE tissues, 3D multi-omic reconstruction, Direct-Seq demonstrations for T- and B-cell receptor sequencing in tissue, and the company’s Spatial Technology Access Services program. In addition, corporate news covers events such as a 1-for-30 reverse stock split to address Nasdaq’s minimum bid price requirement, the receipt of acquisition proposals, the definitive merger agreement with an affiliate of Deerfield Management Company, L.P., and the closing of the Deerfield acquisition after stockholder approval.
Because Singular Genomics has stated that it now operates as a private company and has requested delisting from Nasdaq, the OMIC news feed serves as a record of its public-company history, technology development updates and key strategic decisions during its time as a listed issuer.
Singular Genomics Systems (Nasdaq: OMIC) will present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida. The presentation is scheduled for Wednesday, June 12, 2024, at 7:40 a.m. PT / 10:40 a.m. ET. Management will participate in a fireside chat, and a live and recorded webcast will be available at investor.singulargenomics.com. Singular Genomics leverages novel next-generation sequencing (NGS) and spatial multiomics technologies to support researchers and clinicians.
Singular Genomics (Nasdaq: OMIC) reported its Q1 2024 financial results and highlighted recent achievements. Revenue for the quarter stood at $0.4 million, primarily from one G4 instrument sale and consumables. The company shipped six G4 systems, totaling 30 commercial units. Gross profit was negative $0.4 million, and operating expenses were $26.4 million, leading to a net loss of $25.0 million ($0.34 per share). Singular Genomics aims to launch its G4X spatial sequencer in 2025 and continues to support its existing customer base and expand its spatial services.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) will announce its first quarter 2024 financial results on May 14, 2024, after the market closes. The company focuses on next-generation sequencing and spatial multiomics technologies. The management will host a conference call to discuss the results. Investors can join the call or access the webcast on investor.singulargenomics.com.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.